Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 11, 2021

SELL
$187.49 - $221.1 $1.16 Million - $1.36 Million
-6,169 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $145,949 - $170,123
-705 Reduced 10.26%
6,169 $1.33 Million
Q4 2020

Feb 10, 2021

SELL
$207.01 - $276.09 $3,519 - $4,693
-17 Reduced 0.25%
6,874 $1.63 Million
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $5,879 - $6,971
23 Added 0.33%
6,891 $1.88 Million
Q2 2020

Aug 10, 2020

SELL
$225.48 - $295.8 $55,919 - $73,358
-248 Reduced 3.49%
6,868 $1.99 Million
Q1 2020

Apr 20, 2020

SELL
$199.77 - $247.81 $107,076 - $132,826
-536 Reduced 7.0%
7,116 $1.69 Million
Q4 2019

Jan 31, 2020

SELL
$166.71 - $223.91 $40,510 - $54,410
-243 Reduced 3.08%
7,652 $1.68 Million
Q3 2019

Oct 31, 2019

BUY
$166.23 - $187.09 $12,965 - $14,593
78 Added 1.0%
7,895 $1.34 Million
Q2 2019

Aug 07, 2019

SELL
$164.61 - $190.37 $16,625 - $19,227
-101 Reduced 1.28%
7,817 $1.43 Million
Q1 2019

Apr 25, 2019

BUY
$163.73 - $194.7 $47,317 - $56,268
289 Added 3.79%
7,918 $1.46 Million
Q4 2018

Feb 01, 2019

SELL
$151.91 - $192.21 $24,457 - $30,945
-161 Reduced 2.07%
7,629 $1.26 Million
Q3 2018

Nov 13, 2018

SELL
$167.73 - $192.74 $70,782 - $81,336
-422 Reduced 5.14%
7,790 $1.5 Million
Q2 2018

Jul 20, 2018

BUY
$145.72 - $169.96 $9,034 - $10,537
62 Added 0.76%
8,212 $1.4 Million
Q1 2018

May 08, 2018

SELL
$151.6 - $177.13 $65,036 - $75,988
-429 Reduced 5.0%
8,150 $1.33 Million
Q4 2017

Feb 07, 2018

BUY
$137.28 - $155.55 $230,493 - $261,168
1,679 Added 24.33%
8,579 $1.29 Million
Q3 2017

Oct 19, 2017

BUY
$148.13 - $162.24 $1.02 Million - $1.12 Million
6,900
6,900 $1.05 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Ls Investment Advisors, LLC Portfolio

Follow Ls Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ls Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ls Investment Advisors, LLC with notifications on news.